In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback